A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Niemann-Pick Disease, Type C Clinical Trial

Official title:

Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05163288
• Other study ID #: IB1001-301
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 30, 2022
• Est. completion date: November 2024

Study information

• Verified date: September 2023
• Source: IntraBio Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

Description:

This is a multinational, randomized, placebo-controlled, double-blinded, cross-over Phase III study that will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) versus Placebo for the treatment of Niemann-Pick type C disease (NPC). Patients will be assessed during three study periods: a baseline period (approximately 2-weeks), after which they will be randomized (1:1) to receive treatment with IB1001 or Placebo for approximately 12-weeks during the first intervention period ("Period I"). Following Period I, patients will crossover to receive the opposite treatment (IB1001 or Placebo) for approximately 12-weeks during a second intervention period ("Period II). Patients will be assessed twice during each study period. Patients who have participated in the study may be offered the opportunity to roll over into an Extension Phase, which is planned to allow patients to have further access to IB1001.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: November 2024
• Est. primary completion date: June 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent signed by the patient and/or their legal representative/ parent/ impartial witness

2. Male or female aged =4 years with a confirmed genetic diagnosis of NPC at the time of signing informed consent.

3. Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose and confirm to continue through 28 days after the last dose) or using one of the following highly effective contraceptives (i.e. results in <1% failure rate when used consistently and correctly) 14 days prior

to the first dose continuing through 28 days after the last dose:

1. intrauterine device (IUD);

2. surgical sterilization of the partner (vasectomy for 6 months minimum);

3. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal);

4. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable);

5. intrauterine hormone releasing system (IUS);

6. bilateral tubal occlusion.

4. Females of non-childbearing potential who have undergone one of the following

sterilization procedures at least 6 months prior to the first dose:

1. hysteroscopic sterilization;

2. bilateral tubal ligation or bilateral salpingectomy;

3. hysterectomy;

4. bilateral oophorectomy; OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH analysis for postmenopausal women will be done at screening. FSH levels should be in the postmenopausal range as determined by the central laboratory.

5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion criteria 3 or 4. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male.

6. If male, patient agrees not to donate sperm from the first dose until 90 days after their last dose.

7. Patients must fall within:

a) A SARA score of 7 = X = 34 points (out of 40) AND b) Either: i. Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale OR ii. Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI subtest) in 20 = X =150 seconds.

8. Weight =15 kg at screening.

9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of NPC including those on the prohibited medication list. Non-prohibited medications/therapies (authorized medicines for NPC [e.g. miglustat], speech therapy,

and physiotherapy) are permitted provided:

1. The Investigator does not believe the medication/therapy will interfere with the study protocol/results

2. Patients have been on a stable dose/duration and type of therapy for at least 42 days before Visit 1 (Baseline 1)

3. Patients are willing to maintain a stable dose/do not change their therapy throughout the duration of the study.

10. An understanding of the implications of study participation, provided in the written patient information and informed consent by patients or their legal representative/parent, and demonstrates a willingness to comply with instructions and attend required study visits (for children this criterion will also be assessed in parents or appointed guardians).

Exclusion Criteria:

1. Patients who are unable to consistently Patients who have any known hypersensitivity

or history of hypersensitivity to:

1. Acetyl-Leucine (DL-, L-, D-) or derivatives.

2. Excipients the IB1001 sachet (namely isomalt, hypromellose, and strawberry flavour).

3. Excipients the placebo sachet (namely isomalt, hypromellose, strawberry flavour, citric acid, microcrystalline cellulose, lactose, denatonium benzoate).

2. Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1. At the discretion of the investigator, Medical Monitor, and Sponsor, the washout period for specific IMPs may be longer based on the pharmacological activity and pharmacokinetics of the drug.

3. Patients with a physical, cognitive, or psychiatric condition which, at the investigator's discretion and in consultation with the Medical Monitor and Sponsor (as applicable), may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study, i.e. reliably perform study assessments.

4. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol.

5. Current or planned pregnancy or women who are breastfeeding.

6. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments.

7. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments.

8. Patients unwilling and/or not able to undergo a 42 day period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6.

1. N-Acetyl-DL-Leucine (e.g. Tanganil®);

2. N-Acetyl-L-Leucine (prohibited if not provided as IMP in the IB1001-301 trial);

3. Sulfasalazine;

4. Rosuvastatin. -

Related Conditions & MeSH terms

• Aphasia, Primary Progressive
• Frontotemporal Dementia
• Niemann-Pick Disease, Type C
• Niemann-Pick Diseases
• Pick Disease of the Brain

Intervention

Drug:
• N-Acetyl-L-Leucine
N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

Other:
• Placebo
Matching Placebo Sachet

Locations

Country	Name	City	State
Australia	The Royal Melbourne Hospital	Parkville	Victoria
Czechia	First Faculty of Medicine, Charles University Hospital Prague	Praha
Germany	University of Giessen	Gießen
Germany	University of Hamburg	Hamburg
Germany	SphinCS - Institute of Clinical Science in Lysosomal Storage Disorders	Hochheim
Germany	Ludwig Maximilian University of Munich	München
Germany	University Hospital Münster	Münster
Netherlands	Amsterdam UMC	Amsterdam
Slovakia	Comenius University in Bratislva	Bratislava
Switzerland	University Hospital Bern Inselspital	Bern
United Kingdom	Great Ormond Street Hospital	London
United Kingdom	Royal Free London NHS Foundation Trust	London
United Kingdom	Royal Manchester Children's Hospital	Manchester
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
IntraBio Inc

Countries where clinical trial is conducted

United States,  Australia,  Czechia,  Germany,  Netherlands,  Slovakia,  Switzerland,  United Kingdom, 

References & Publications (3)

Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K, Raethjen J, Ramaswami U, Sharma R, Schneider SA. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J N — View Citation

Cortina-Borja M, Te Vruchte D, Mengel E, Amraoui Y, Imrie J, Jones SA, I Dali C, Fineran P, Kirkegaard T, Runz H, Lachmann R, Bremova-Ertl T, Strupp M, Platt FM. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease — View Citation

Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 2020 Dec 20;3(1):fcaa148 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS)		End of Period I (week 12) vs. End of Period 2 (week 24)
Other	5-Domain Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS)		End of Period I (week 12) vs. End of Period 2 (week 24)
Other	Investigator's / Caregiver's / Patient's Clinical Global Impressions (CGI)		End of Period I (week 12) vs. End of Period 2 (week 24)
Other	Modified Scale for the Assessment and Rating of Ataxia (all jurisdictions except US)		End of Period I (week 12) vs. End of Period 2 (week 24)
Primary	Scale for the Assessment and Rating of Ataxia (all jurisdictions except US)		End of Period I (week 12) vs. End of Period 2 (week 24)
Primary	Modified Scale for the Assessment and Rating of Ataxia (US only)		End of Period I (week 12) vs. End of Period 2 (week 24)
Secondary	Spinocerebellar Ataxia Functional Index (SCAFI)		End of Period I (week 12) vs. End of Period 2 (week 24)
Secondary	Modified Disability Rating Scale		End of Period I (week 12) vs. End of Period 2 (week 24)
Secondary	Physician's / Caregiver's / Patient's Clinical Global Impressions (CGI)		End of Period I (week 12) vs. End of Period 2 (week 24)
Secondary	EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale		End of Period I (week 12) vs. End of Period 2 (week 24)
Secondary	Scale for the Assessment and Rating of Ataxia (US only)		End of Period I (week 12) vs. End of Period 2 (week 24)